君实生物(688180.SH)披露2025年A股股票期权激励计划(草案)，公司拟授予的股票期权数量为2617.5871 万份(首次授予股票期权2536万份)，首次及预留授予的股票期权的行权价格为46.67元/份。首次授予股 票期权的激励对象共计251人。 本激励计划有效期为自股票期权首次授权之日起至激励对象获授的股票期权全部行权或注销完毕之日 止，最长不超过48个月。 ...

Core Viewpoint - Junshi Biosciences (688180.SH) announced that its subsidiary, Shanghai Juntao Biopharmaceutical Technology Co., Ltd., received approval from the National Medical Products Administration for the clinical trial of JT118 injection, aimed at preventing monkeypox virus infection [1] Group 1: Company Developments - The clinical trial application for JT118 injection has been approved, allowing the company to conduct trials for its use against monkeypox virus [1] - JT118 is a "two-in-one" recombinant protein vaccine composed of monkeypox virus antigens A35 (extracellular membrane virus antigen) and M1 (intracellular mature virus antigen) [1] - The vaccine retains the structural epitopes of both natural antigens A35 and M1 while significantly increasing molecular weight through multi-antigen fusion, enhancing immune response [1] Group 2: Industry Context - Monkeypox is a zoonotic viral disease caused by the monkeypox virus, classified under the Orthopoxvirus genus of the Poxviridae family [1] - The monkeypox virus replicates in two different forms: extracellular membrane virus and intracellular mature virus, both of which are infectious [1]

本激励计划有效期为自股票期权首次授权之日起至激励对象获授的股票期权全部行权或注销完毕之日 止，最长不超过48个月。 智通财经APP讯，君实生物(688180.SH)披露2025年A股股票期权激励计划(草案)，公司拟授予的股票期 权数量为2617.5871万份(首次授予股票期权2536万份)，首次及预留授予的股票期权的行权价格为46.67 元/份。首次授予股票期权的激励对象共计251人。 ...

格隆汇9月2日丨君实生物(688180.SH)公布，公司控股子公司上海君拓生物医药科技有限公司收到国家 药品监督管理局核准签发的《药物临床试验批准通知书》，JT118注射液（项目代号"JT118"）的临床试 验申请获得批准。 ...

Group 1 - Junshi Biosciences (688180.SH) announced a stock option incentive plan for 2025, proposing to grant a total of 26.175871 million stock options, which accounts for approximately 2.55% of the company's total share capital at the time of the announcement [1] - The initial grant of stock options is 25.36 million, representing about 2.47% of the company's total share capital at the time of the announcement, and 96.88% of the total options to be granted [1] - A reserve of 815871 stock options is planned, which accounts for approximately 0.08% of the company's total share capital at the time of the announcement, making up 3.12% of the total options to be granted [1]

JT118是由猴痘病毒抗原A35(胞外囊膜病毒抗原)和M1(胞内成熟病毒抗原)串联融合组成的"二合一"重组 蛋白疫苗，拟主要用于预防猴痘病毒感染。 人民财讯9月2日电，君实生物(688180)9月2日晚间公告，公司控股子公司上海君拓生物医药科技有限公 司近日收到国家药监局核准签发的《药物临床试验批准通知书》，JT118注射液(项目代号"JT118")的临 床试验申请获得批准。 ...

君实生物公告，控股子公司上海君拓生物医药科技有限公司收到国家药品监督管理局核准签发的《药物 临床试验批准通知书》，JT118 注射液（项目代号"JT118"）的临床试验申请获得批准。JT118 是由猴痘 病毒抗原 A35 和 M1 串联融合组成的"二合一"重组蛋白疫苗，拟主要用于预防猴痘病毒感染。 ...

Core Viewpoint - Junshi Bioscience's stock price has shown significant growth this year, with a 68.90% increase, despite a recent decline in trading activity and net outflow of funds [2][1]. Company Overview - Junshi Bioscience, established on December 27, 2012, and listed on July 15, 2020, is located in Shanghai and focuses on the research and commercialization of monoclonal antibody drugs and other therapeutic protein drugs [2]. - The company operates in the pharmaceutical and biotechnology sector, specifically in the bioproducts category, and is involved in various concepts including monkeypox, mid-cap, margin trading, and biomedicine [2]. Financial Performance - For the first half of 2025, Junshi Bioscience reported revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, showing a year-on-year increase of 36.01% [2]. Shareholder Information - As of June 30, 2025, the number of shareholders increased to 31,200, up by 5.88%, with an average of 24,543 circulating shares per person, a decrease of 5.56% [2]. - The top ten circulating shareholders include notable ETFs, with changes in their holdings indicating varying levels of investment interest [3].

Group 1 - On September 1, Junshi Biosciences experienced a stock price increase of 4.71% with a trading volume of 1.08 billion yuan [1] - The financing data for Junshi Biosciences on the same day showed a net financing purchase of 7.418 million yuan, with a total financing balance of 1.3 billion yuan, which is 3.57% of its market capitalization [1] - The company's short selling data indicated a short selling balance of 9.655 million yuan, exceeding the 80th percentile of the past year, indicating a high level of short interest [1] Group 2 - As of June 30, Junshi Biosciences had 31,200 shareholders, an increase of 5.88% from the previous period, while the average number of circulating shares per person decreased by 5.56% to 24,543 shares [2] - For the first half of 2025, Junshi Biosciences reported a revenue of 1.168 billion yuan, representing a year-on-year growth of 48.64%, while the net profit attributable to shareholders was -413 million yuan, an increase of 36.01% year-on-year [2] - Among the top ten circulating shareholders, Huaxia SSE STAR 50 ETF held 29.7167 million shares, a decrease of 536,700 shares, while E Fund SSE STAR 50 ETF increased its holdings by 630,000 shares to 22.2132 million shares [2]

Core Viewpoint - Chint Electric announced the termination of the IPO plan for its subsidiary Chint Aneng Digital Energy, citing strong business performance and growth as reasons for the decision [1][4]. Group 1: Company Overview - Chint Aneng focuses on the household photovoltaic sector, aiming to become a digital and service-oriented comprehensive energy service provider, covering all lifecycle stages from development to after-sales service [2]. - Prior to the IPO termination, Chint Aneng had planned to raise 6 billion yuan through the listing [1]. Group 2: Financial Performance - Chint Aneng's revenue and profit have shown consistent growth over the past three years, with projected revenues of 13.704 billion yuan, 29.606 billion yuan, and 31.826 billion yuan for 2022, 2023, and 2024 respectively. Net profits are expected to be 1.753 billion yuan, 2.604 billion yuan, and 2.861 billion yuan for the same years [2]. Group 3: IPO Process and Challenges - The Shanghai Stock Exchange accepted Chint Aneng's listing application in September 2023, and the company had completed a round of inquiry responses before the IPO was withdrawn [2]. - The exchange raised concerns regarding Chint Aneng's diverse business operations and the significant changes in business proportions, requesting detailed disclosures on business development and future plans [2]. Group 4: Strategic Direction - Chint Aneng's future direction was highlighted during its 10th anniversary strategic renewal conference, where the company expressed its vision to become a global leader in comprehensive energy services, focusing on green and low-carbon energy solutions [4][5]. - The company aims to innovate its business model by integrating new energy investment, development, construction, operation, and electricity sales into a comprehensive service ecosystem [4].